Latest results from the dose‐expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer’s disease

Abstract

Background: The anti‐amyloid Brainshuttle™ antibody trontinemab is currently being investigated in the Phase Ib/IIa Brainshuttle™ AD study in people with mild cognitive impairment due to Alzheimer’s disease (AD) or mild‐to‐moderate AD (NCT04639050).

The paper